• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,100.47 109.25
( 0.14%)
Global Indices
Nasdaq
51,823.54 -118.08
(-0.23%)
Dow Jones
7,358.68 -19.81
(-0.27%)
Hang Seng
69,065.93 -3,300.41
(-4.56%)
Nikkei 225
10,515.14 -14.75
(-0.14%)
Forex
USD-INR
94.55 -0.19
(-0.20%)
EUR-INR
107.36 -0.64
(-0.59%)
GBP-INR
124.56 -0.65
(-0.52%)
JPY-INR
0.58 0.00
(-0.30%)

EQUITY - MARKET SCREENER

Karur Vysya Bank Ltd
Industry :  Banks - Private Sector
BSE Code
ISIN Demat
Book Value()
590003
INE036D01028
145.9672036
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KARURVYSYA
11.17
28048.05
EPS(TTM)
Face Value()
Div & Yield %
25.97
2
0.9
 

Bajaj Healthcare secures SEC recommendation for Cenobamate tablets
Jun 27,2026
Bajaj Healthcare specializes in manufacturing intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.

The company reported a standalone net loss of Rs 22.85 crore in Q4 FY26, compared with a net profit of Rs 11.17 crore posted in Q4 FY25. Revenue from operations shed 0.91% YoY to Rs 153.05 crore in Q4 FY26, compared with Rs 154.47 crore in the corresponding quarter last year.

The counter declined 1.91% to settle at Rs 305.50 on the BSE.